<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124122</url>
  </required_header>
  <id_info>
    <org_study_id>FDA IND# 13710-Protocol 2</org_study_id>
    <secondary_id>5U01AT002733</secondary_id>
    <nct_id>NCT02124122</nct_id>
  </id_info>
  <brief_title>Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru</brief_title>
  <official_title>Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación Benéfica Prisma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to assess the safety and tolerability of Lactobacillus reuteri (Lr)
      strain DSM 17938 in healthy children in Peru. It is a preliminary study in support of a
      clinical trial to assess safety and efficacy of L. reuteri for treatment of pediatric
      diarrhea in Peru.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I blinded randomized study of the safety and tolerability of Lactobacillus
      reuteri DSM 17938 given daily for a period of five consecutive days. Upon enrollment subjects
      will be randomized to one of two treatment groups in a ratio of treatment to placebo of 2:1.
      Subjects will be randomized to receive either:

      A. Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose,
      given once daily for a five-day treatment period that corresponds to a dose of the closely
      related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic.
      The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid
      found in the original BioGaia strain (L. reuteri ATCC 55730).

      B. Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing
      the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm,
      Sweden).

      In the first 30 subjects randomized, administration of each dose of the study preparation
      drops (A or B above) will be immediately followed by offering 2 ounces of flavored PediaSure
      ® (Abbott Laboratories) nutritional supplement to each child. The second 30 subjects enrolled
      will not be offered PediaSure ® after product administration. This format will also allow us
      to assess the impact of concurrent administration of a buffering non-lactose containing
      formula with prebiotic nutritional properties on intestinal colonization with L. reuteri by
      PCR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Positive Blood Culture for L Reuteri</measure>
    <time_frame>Participants are followed an average of 36 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Daily Temperature</measure>
    <time_frame>Study days 1-5, 8,12, 15, 18, 28, and 36</time_frame>
    <description>Mean of body temperatures recorded on study days listed, averaged across all participants at all time points</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lactobacillus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lactobacillus reuteri</intervention_name>
    <description>Probiotic</description>
    <arm_group_label>Lactobacillus</arm_group_label>
    <other_name>BioGaia Probiotic Drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children ages 2-5 years with no exclusion criteria

        Exclusion Criteria:

          -  1) No enrollment of family members in households where any of the following are
             present:

               1. Another study participant in the household

               2. Pregnancy or current breastfeeding by any household member

               3. Presence of an infant under age 6 months living in the household

               4. Presence of immune suppressed individuals or use of immunosuppressive agents
                  (including but not limited to corticosteroids and methotrexate, etc.) by any
                  household member

               5. Presence of a serious congenital anomaly or chronic medical condition that in the
                  opinion of the investigators would contraindicate participation in any household
                  member, including history of gastrointestinal surgery, chronic gastrointestinal
                  illness, abnormal intestinal anatomy, or abnormal bowel functionality

                  2) Allergy to penicillin or cephalosporins or gentamicin 3) History of antibiotic
                  use in the last 30 days 4) Use of probiotic products within the past 90 days,
                  including masato (local product with fermenting bacteria) and yogurt products
                  containing live bacterial cultures.

                  5) History of diarrheal illness within the past 30 days 6) Presence of fever or a
                  pre-existing adverse event monitored in the study 7) Positive results on serum
                  diagnostic tests for antibodies to HIV.

                  Testing for Hepatitis B core antigen, and Hepatitis C is not necessary in
                  children as in adults, since there is universal vaccination for Hepatitis B among
                  children in this community, and both forms of hepatitis are rare and largely
                  asymptomatic in this age group.

                  8) Presence of severe anemia, defined as serum hemoglobin &lt; 8 gm/dL

                  9) Out of range laboratory values for tests monitored as potential adverse
                  events, as described in Appendix 2, B. LABORATORY VALUES, and detected based on
                  Day 0 blood test results. However, subjects will only be excluded based on serum
                  hemoglobin if they meet exclusion criterion 8.

                  10) Pre-enrollment stool sample (collected within 14 days of Day 1 of the study)
                  is positive for L. reuteri by PCR.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Oberhelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane School of Public Health and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret N Kosek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community of Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>Loreto</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <results_first_submitted>December 16, 2016</results_first_submitted>
  <results_first_submitted_qc>March 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2017</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University School of Medicine</investigator_affiliation>
    <investigator_full_name>Richard A. Oberhelman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Focus</keyword>
  <keyword>safety</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lactobacillus</title>
          <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
Lactobacillus reuteri: Probiotic</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lactobacillus</title>
          <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
Lactobacillus reuteri: Probiotic</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.04" spread="1.278"/>
                    <measurement group_id="B2" value="3.31" spread="1.080"/>
                    <measurement group_id="B3" value="3.81" spread="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Positive Blood Culture for L Reuteri</title>
        <time_frame>Participants are followed an average of 36 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
Lactobacillus reuteri: Probiotic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Blood Culture for L Reuteri</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Daily Temperature</title>
        <description>Mean of body temperatures recorded on study days listed, averaged across all participants at all time points</description>
        <time_frame>Study days 1-5, 8,12, 15, 18, 28, and 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
Lactobacillus reuteri: Probiotic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Temperature</title>
          <description>Mean of body temperatures recorded on study days listed, averaged across all participants at all time points</description>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.50" spread="0.288"/>
                    <measurement group_id="O2" value="36.45" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 through Day 28 after day 0</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lactobacillus</title>
          <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
Lactobacillus reuteri: Probiotic</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>At least one episode of diarrhea during 28 days of active surveillance</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Scabies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper repiratory infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="41"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Oberhelman</name_or_title>
      <organization>Tulane SPHTM</organization>
      <phone>5049882511</phone>
      <email>oberhel@tulane.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

